Tucci Marco

25PUBLICATIONS
134CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 04, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.

|May 28, 2025
Immunotherapy in Advanced Cutaneous Melanoma: From the Optimal Treatment Duration to the Impact on Survival in Case of Early Discontinuation Due to Immune-Related Adverse Events.

Giacomo Triggiano, Gaetano Pezzicoli, Marco Tucci

|Dec 17, 2024
Retrospective-Prospective Observational Study of Italian Patients Treated in Melanoma Adjuvant Cohort MAP-MADAM (Maximing ADjuvAnt MAP): Interim Analysis.

Francesca Consoli, Marco Tucci, Jacopo Pigozzo

|Jan 22, 2024
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry.

Bruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca

|May 27, 2023
Checkpoint Inhibitor-Induced Colitis: An Update.

Giuseppe Losurdo, Daniele Angelillo, Nicolas Favia

|May 01, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.

Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary

Pageof 5

Frequent Collaborators

4 joint publications

Francesco Mannavola

4 joint publications

Maria Chiara Sergi

4 joint publications

Valeria Internò

4 joint publications

Paolo A Ascierto